ENDPOINTS

06.2.2023

Exclusive: Affini-T taps Sanofi alum to lead hunt for partnerships; Alkermes locks in CEO for oncology spinout

News

ENDPOINTS

04.19.2023

KRAS, one of cancer’s toughest targets, sees a surge of new therapies trying to limit side effects: #AACR23

News

ENDPOINTS

11.28.2022

Endpoints’ 10 biggest stories of 2022

News

ENDPOINTS

09.22.2022

The Endpoints 11: The top private biotechs in pursuit of new drugs. Pushing the envelope with powerful new technologies

News

Business Insider

07.28.2022

Meet the 23 biotech startups that are set to take off in the next 12 months, according to top VCs

News

ENDPOINTS

07.26.2022

‘Go quickly’: Amgen R&D vet Dirk Nagorsen jumps to a startup with big plans for TCRs

News

ENDPOINTS

06.15.2022

No introductions necessary: A TCR upstart with deep-pocket backers partners with one of the new players in the hot gene editing field

News

GeekWire

03.22.2022

Fred Hutch spinout Affini-T Therapeutics lands $175M for cell therapies to treat solid tumors

News

ENDPOINTS

03.22.2022

A new cell therapy startup from an immunotherapy pioneer raises $175M in KRAS quest

News

Fierce Biotech

03.22.2022

Bayer-backed Affini-T snags $175M to enter increasingly crowded KRAS-cancer field

News

Boston Globe

03.22.2022

Affini-T Therapeutics launches with $175 million for cancer treatments

News

Boston Business Journal

03.22.2022

Vida, Bayer throw weight behind $175M T-cell startup

News

Business Insider

03.22.2022

See the 24-slide pitch deck a new biotech startup just used to raise $175 million to develop the next cancer breakthrough

News

BioSpace

01.14.2022

New Cell Therapy Player Makes Public Debut at JPM

News

GeekWire

01.13.2022

Juno co-founder launches ambitious new startup with Fred Hutch colleagues to treat cancer

News

STAT

01.13.2022

A new biotech startup looks to sidestep a key problem with CAR-T cancer therapies

News